Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.
SINAPPS2 Trial - immunotherapy for antibody associated psychosis

 

QUICK ACCESS
PiP2 Recruitment Training for Clinicians
SINAPPS2 Protocol
PPiP2 Participating NHS Organisations

Psychotic illnesses like schizophrenia and bipolar disorder are serious mental illnesses of unknown cause. There is an urgent need to discover the basis of these disorders, and to develop new treatments.  There are many lines of evidence to suggest that a proportion of psychosis has an immune basis. We are a multidisciplinary group of clinicians and researchers who are exploring this possibility, using a range of approaches.

We have found that some people with psychosis have particular antibodies that are known to cause another serious brain disorder - encephalitis.  It is possible that these same antibodies are also causing psychosis in some people, and we are undertaking research to establish whether this is the case.

We undertake clinical trials of immune therapies in people with psychosis, and experimental medicine studies to examine the interaction between the immune system and the brain.

We propose that in some patients the cause of psychosis may be antibodies binding to neuronal membrane targets (NMDAR, LGI1, GABA-A and other), especially NMDA receptors, in the brain. The hypothesis underlying the SINAPPS2 trial is that these antibodies may be pathogenic and responsible for isolated psychosis (antibody-mediated psychosis).

We are currently conducting the SINAPPS2 trial to test whether immunotherapy is an effective treatment for antibody-associated psychosis. It is a randomised phase II double-blinded placebo-controlled trial of intravenous immunoglobulin and rituximab in patients with antibody-associated psychosis. Adult patients (16-60 years old) with antibody-associated psychosis are invited to one of the NHS hospitals participating in the study, where they are assessed and assisted by a team of SINAPPS2 clinicians and researchers. Eligible patients are randomly allocated to receive either intravenous immunoglobulin combined with rituximab or placebo treatment and they will be followed for at least 12 months.  For more information about the SINAPPS2 trial click here.